• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4623024)   Today's Articles (5252)   Subscriber (49407)
For: Neu HC, Saha G, Chin NX. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother 1989;33:1795-800. [PMID: 2589845 PMCID: PMC172757 DOI: 10.1128/aac.33.10.1795] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]  Open
Number Cited by Other Article(s)
1
Turner J, Muraoka A, Bedenbaugh M, Childress B, Pernot L, Wiencek M, Peterson YK. The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition. Front Microbiol 2022;13:807955. [PMID: 35401470 PMCID: PMC8988990 DOI: 10.3389/fmicb.2022.807955] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 02/14/2022] [Indexed: 12/05/2022]  Open
2
Stewart AG, Harris PNA, Henderson A, Schembri MA, Paterson DL. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. J Antimicrob Chemother 2021;75:2384-2393. [PMID: 32443141 DOI: 10.1093/jac/dkaa183] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]  Open
3
Sader HS, Jones RN. Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Rev Anti Infect Ther 2014;5:29-43. [PMID: 17266451 DOI: 10.1586/14787210.5.1.29] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
4
Al-Badr AA, Alasseiri FA. Cefdinir. PROFILES OF DRUG SUBSTANCES, EXCIPIENTS, AND RELATED METHODOLOGY 2014;39:41-112. [PMID: 24794905 DOI: 10.1016/b978-0-12-800173-8.00002-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
5
Development and validation of a rapid HPLC method for the determination of cefdinir in beagle dog plasma integrated with an automatic on-line solid-phase extraction following protein precipitation in the 96-well plate format. J Chromatogr B Analyt Technol Biomed Life Sci 2012;895-896:83-8. [DOI: 10.1016/j.jchromb.2012.03.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Revised: 03/05/2012] [Accepted: 03/10/2012] [Indexed: 11/30/2022]
6
Effect of preparation method on complexation of Cefdinir with β-cyclodextrin. J INCL PHENOM MACRO 2009. [DOI: 10.1007/s10847-009-9666-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
7
Klaubert DH, Essery JM, Barrett JF. New cephalosporins in development pipelines. Expert Opin Investig Drugs 2008. [DOI: 10.1517/13543784.3.2.133] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
8
Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 2004;64:1433-64. [PMID: 15212560 DOI: 10.2165/00003495-200464130-00004] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
9
Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn Microbiol Infect Dis 2003;47:515-25. [PMID: 14596971 DOI: 10.1016/s0732-8893(03)00165-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
10
González M, Rodríguez Z, Tolón B, Rodríguez JC, Velez H, Valdés B, López MA, Fini A. An alternative procedure for preparation of cefdinir. FARMACO (SOCIETA CHIMICA ITALIANA : 1989) 2003;58:409-18. [PMID: 12767379 DOI: 10.1016/s0014-827x(03)00063-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
11
Guay DRP. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 2002;24:473-89. [PMID: 12017394 DOI: 10.1016/s0149-2918(02)85125-6] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
12
Guay DR. Cefdinir: an expanded-spectrum oral cephalosporin. Ann Pharmacother 2000;34:1469-77. [PMID: 11144705 DOI: 10.1345/aph.19407] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
13
Guay DR. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr Infect Dis J 2000;19:S141-6. [PMID: 11144395 DOI: 10.1097/00006454-200012001-00002] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
14
Birnbaumer D, Fernández-Frackelton M. The new antibiotics. Emerg Med Clin North Am 2000;18:671-708. [PMID: 11130933 DOI: 10.1016/s0733-8627(05)70153-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
15
Leigh AP, Nemeth MA, Keyserling CH, Hotary LH, Tack KJ. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. Clin Ther 2000;22:818-25. [PMID: 10945508 DOI: 10.1016/s0149-2918(00)80054-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
16
Nemeth MA, McCarty J, Gooch WM, Henry D, Keyserling CH, Tack KJ. Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Clin Ther 1999;21:1873-81. [PMID: 10890259 DOI: 10.1016/s0149-2918(00)86735-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
17
Nemeth MA, Gooch WM, Hedrick J, Slosberg E, Keyserling CH, Tack KJ. Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis. Clin Ther 1999;21:1525-32. [PMID: 10509847 DOI: 10.1016/s0149-2918(00)80007-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
18
Tack KJ, Henry DC, Gooch WM, Brink DN, Keyserling CH. Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Antimicrob Agents Chemother 1998;42:1073-5. [PMID: 9593129 PMCID: PMC105747 DOI: 10.1128/aac.42.5.1073] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]  Open
19
Tack KJ, Littlejohn TW, Mailloux G, Wolf MM, Keyserling CH. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin Ther 1998;20:244-56. [PMID: 9589816 DOI: 10.1016/s0149-2918(98)80088-x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
20
Fukuoka T, Kawada H, Kitayama A, Koga T, Kubota M, Harasaki T, Kamai Y, Ohya S, Yasuda H, Iwata M, Kuwahara S. Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice. Antimicrob Agents Chemother 1998;42:23-7. [PMID: 9449255 PMCID: PMC105450 DOI: 10.1128/aac.42.1.23] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]  Open
21
Fukuoka T, Ohya S, Utsui Y, Domon H, Takenouchi T, Koga T, Masuda N, Kawada H, Kakuta M, Kubota M, Ishii C, Ishii C, Sakagawa E, Harasaki T, Hirasawa A, Abe T, Yasuda H, Iwata M, Kuwahara S. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob Agents Chemother 1997;41:2652-63. [PMID: 9420035 PMCID: PMC164185 DOI: 10.1128/aac.41.12.2652] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]  Open
22
Tanaka M, Hohmura M, Nishi T, Sato K, Hayakawa I. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640. Antimicrob Agents Chemother 1997;41:1260-8. [PMID: 9174181 PMCID: PMC163897 DOI: 10.1128/aac.41.6.1260] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]  Open
23
Tack KJ, Keyserling CH, McCarty J, Hedrick JA. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob Agents Chemother 1997;41:739-42. [PMID: 9087480 PMCID: PMC163785 DOI: 10.1128/aac.41.4.739] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]  Open
24
Blandino G, Aleo G, Caccamo F, Nicolosi VM, Siracusa V, Speciale A. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production. J Chemother 1996;8:193-9. [PMID: 8808715 DOI: 10.1179/joc.1996.8.3.193] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
25
Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin. Antimicrob Agents Chemother 1995;39:2544-51. [PMID: 8585742 PMCID: PMC162981 DOI: 10.1128/aac.39.11.2544] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]  Open
26
Richer M, Allard S, Manseau L, Vallée F, Pak R, LeBel M. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses. Antimicrob Agents Chemother 1995;39:1082-6. [PMID: 7625793 PMCID: PMC162687 DOI: 10.1128/aac.39.5.1082] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]  Open
27
Wittmann DH. The role of cefotaxime in the treatment of surgical infections. Diagn Microbiol Infect Dis 1995;22:173-82. [PMID: 7587036 DOI: 10.1016/0732-8893(95)00101-f] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
28
Annotated References. Expert Opin Investig Drugs 1994. [DOI: 10.1517/13543784.3.2.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
29
Buschelman BJ, Jones RN, Bale MJ. Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci. J Clin Microbiol 1994;32:565-7. [PMID: 8150978 PMCID: PMC263080 DOI: 10.1128/jcm.32.2.565-567.1994] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]  Open
30
Cohen MA, Joannides ET, Roland GE, Meservey MA, Huband MD, Shapiro MA, Sesnie JC, Heifetz CL. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability. Diagn Microbiol Infect Dis 1994;18:31-9. [PMID: 8026155 DOI: 10.1016/0732-8893(94)90131-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
31
Cohen MA, Wold SA, Meservey MA, Gage JW, Heifetz CL, Mailloux GB, Roland GE, Yoder SL. In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models. Diagn Microbiol Infect Dis 1994;18:41-7. [PMID: 8026156 DOI: 10.1016/0732-8893(94)90132-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
32
Rodrigues JN, Amaral JL, Leme IL, Pignatari A, Wey S, Hollis R, Pfaller MA, Jones RN. Molecular epidemiology and antimicrobial susceptibility testing. Testing of quinolone-resistant Staphylococcus aureus strains isolated in Brazil. Diagn Microbiol Infect Dis 1993;16:9-16. [PMID: 8381066 DOI: 10.1016/0732-8893(93)90124-p] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
33
Jones RN, Erwin ME. Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin. Diagn Microbiol Infect Dis 1992;15:693-701. [PMID: 1478050 DOI: 10.1016/0732-8893(92)90073-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
34
Gerlach EH, Jones RN, Allen SD, Koontz FP, Murray PR, Pfaller MA, Washington JA, Erwin ME. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. Diagn Microbiol Infect Dis 1992;15:537-43. [PMID: 1424507 DOI: 10.1016/0732-8893(92)90105-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
35
Scriver SR, Willey BM, Low DE, Simor AE. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens. Eur J Clin Microbiol Infect Dis 1992;11:646-52. [PMID: 1396778 DOI: 10.1007/bf01961677] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
36
Neu HC, Gu JW, Fang W, Chin NX. In vitro activity and susceptibility to hydrolysis of S-1006. Antimicrob Agents Chemother 1992;36:1336-41. [PMID: 1416835 PMCID: PMC190343 DOI: 10.1128/aac.36.6.1336] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]  Open
37
Yourassowsky E, Van der Linden MP, Crokaert F. Comparative kill and growth rates determined with cefdinir and cefaclor and with Streptococcus pneumoniae and beta-lactamase-producing Haemophilus influenzae. Antimicrob Agents Chemother 1992;36:46-9. [PMID: 1590698 PMCID: PMC189223 DOI: 10.1128/aac.36.1.46] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]  Open
38
Bale MJ, Jones RN, Erwin ME, Koontz FP, Gerlach EH, Murray PR, Washington JA. MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. J Clin Microbiol 1992;30:225-6. [PMID: 1310329 PMCID: PMC265027 DOI: 10.1128/jcm.30.1.225-226.1992] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]  Open
39
Jones RN, Erwin ME, Barrett MS. Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella. Diagn Microbiol Infect Dis 1991;14:519-21. [PMID: 1802542 DOI: 10.1016/0732-8893(91)90011-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
40
Murray PR, Allen SD, Erwin ME, Gerlach EH, Jones RN, Koontz FP, Pfaller MA, Washington JA. Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates. Eur J Clin Microbiol Infect Dis 1991;10:776-81. [PMID: 1810737 DOI: 10.1007/bf01972510] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
41
Briggs BM, Jones RN, Erwin ME, Barrett MS, Johnson DM. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Diagn Microbiol Infect Dis 1991;14:425-34. [PMID: 1797457 DOI: 10.1016/0732-8893(91)90069-r] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
42
Pignatari A, Jones RN, Barrett MR, Sesso R, Leme I, Pfaller MA. Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infection. J Chemother 1991;3:108-16. [PMID: 1651997 DOI: 10.1080/1120009x.1991.11739075] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
43
Leggett NJ, Caravaggio C, Rybak MJ. Cefixime. DICP : THE ANNALS OF PHARMACOTHERAPY 1990;24:489-95. [PMID: 2188437 DOI: 10.1177/106002809002400510] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
44
Bauernfeind A, Jungwirth R, Schweighart S, Theopold M. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins]. Infection 1990;18 Suppl 3:S155-67. [PMID: 2079378 DOI: 10.1007/bf01644637] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA